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A B S T R A C T
Purpose: To determine the percentage of childrenwhomﬁrst-line antiepileptic drug treatment failed and
the speciﬁc reasons for the treatment failure in newly diagnosed epilepsy.
Methods: Hospital records were reviewed for 225 children who were newly diagnosed with epilepsy,
started on the ﬁrst antiepileptic drug, and then monitored for approximately 4.2 years.
Results: Of the 225 patients analyzed, the mean age was 7.9  0.6 years at diagnosis. Most of the patients
suffered from primarily generalized tonic-clonic seizures (in 84 patients, 37.3%). 114 patients (50.6%) were
classiﬁed as having idiopathic epilepsy, 64 (28.4%) had symptomatic epilepsy and 47 (20.8%) has cryptogenic
epilepsy. Valproic acid (n: 120, 53.3%), carbamazepine (n: 45, 20%) and oxcarbazepine (n: 31, 13.7%) were the
most frequently prescribed antiepileptic drugs. Overall, 67.5% (n: 152) patients were treated successfully
with the ﬁrst antiepileptic drug. Seventy-three patients failed with the ﬁrst-line antiepileptic drug. Of these
patients, 28 discontinuedmedication because of adverse effects (38.3%), 26 because of lack of efﬁcacy (35.6%)
and 19 (26.02%)because of a combination of inefﬁcacy and adverse effects. Age at diagnosis, seizure, etiology
and antiepileptic drug selection are considered to be associated with drug treatment failure in childhood
epilepsy. Therewas no statistically signiﬁcant effect of any of these variables on ﬁrst-line treatment outcome.
Conclusion: Approximately one-third of the childrenwithnewly diagnosedepilepsy fail theﬁrst prescribed
antiepileptic drug. Adverse effects and lack of efﬁcacy contributed equally to the treatment failures.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy is a group of neurologic conditions characterized by
recurrent, unprovoked seizures. A large proportion of epilepsy
begins in childhood. The prevalence of epilepsy in children has been
estimated at 3.5–7.2 per 1000 children.1 Many types of epilepsy
occur in children, with diagnosis depending on the type of seizure
(simple partial, complex partial, partial becoming generalized,
generalized) and etiology (symptomatic, idiopathic, cryptogenic).
The aimof antiepileptic drug treatment is to reduce epilepsy seizure
frequency with as few side effects while minimising long-term
detrimental effects. Knowing the response to antiepileptic drug
treatment will undoubtedly inﬂuence the treatment strategy in
childhood epilepsy. Data on why children fail medications would
allow better counseling of patients and parents as well. There are
relatively fewer studies examining the tolerability and treatment
failure of antiepileptic drugs in children compared with adults. We
provide a comprehensive and current literature review of the AEDs,
focusing on treatment failure and tolerability data in children.
Previous studies have yielded data for adults suggesting that fewer
than one half of patients become seizure free with the ﬁrst-line* Corresponding author at: Yunus Emre Cad. Yigitler Sok, No: 9/3, 06010 I˙ncirli-
Ankara, Turkey. Tel.: +90 312 3232 995.
E-mail address: petekarhan@yahoo.com.tr (E. Arhan).
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.07.017antiepileptic drug tried,2–6 whereas antiepileptic drug treatment
failure and reasons in children is virtually unknown and few data
address this issuespeciﬁcally.7–9Camﬁeldetal. documentedsuccess
or failure of the initial AED in the ﬁrst year of treatment, as well as
long-term seizure control and remission. They showed that, overall,
in 17% of children the treatmentwith the ﬁrstmedication failed, and
treatment failures of up to 24% were more common in those with
partial seizures (compared with generalized tonic/clonic seizures).7
Dudley et al. found that treatment with the ﬁrst antiepileptic drug
failed in 31.6% of the children.9 An audit of childhood antiepileptic
drug use over a 4-year period in the Netherlands found a 40% failure
rate with the ﬁrst antiepileptic drug prescribed.8
In clinical practice, it would be desirable to better predict the
effectivity of the antiepileptic drug within a short period after
diagnosis. Because studies on the treatment failure and tolerability
of the ﬁrst antiepileptic drug in children are very rare, the present
retrospective study was designed with the objective of determin-
ing the percentage of children whom ﬁrst-line antiepileptic drug
treatment failed and the speciﬁc reasons for the treatment failure.
2. Methods
2.1. Patients and treatment
The study group was identiﬁed from the patient charts of
Pediatric Neurology Department of Gazi University Faculty ofvier Ltd. All rights reserved.
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who were followed by well-established diagnosis of epilepsy as
deﬁned by the International Classiﬁcation of Epilepsies and
Epileptic Syndromes10 and treated with the antiepileptic drugs
for the ﬁrst time.We retrospectively reviewed through the records
of a total of 225 patients aged 0–18 years who were newly
diagnosed with epilepsy and prescribed an antiepileptic drug
during the period from January 2000 to December 2004. Children
who were not treated nor followed for epilepsy, children who had
started treatment elsewhere but came to our center for follow-up
and those diagnosed with febrile seizures were not included in the
chart review. In the study hospital, when the children are
diagnosed with epilepsy, they are followed at our clinic until
they achieve seizure remission and are taken off treatment. To
determine if and why patients failed the ﬁrst-line antiepileptic
drug prescribed, the hospital records of these children were
reviewed for an average of 4.2 years. Seizure freedom was deﬁned
as having no more seizures for the 4.2-year duration of this study
or had no seizures for an adequate period of time (i.e., 2 years). The
ﬁrst prescribed antiepileptic drug was considered as a treatment
failure if (1) it does not seem to control seizure to a signiﬁcant
degree (lack of efﬁcacy)2 causes intolerable adverse effects. If the
antiepileptic drug decreased seizure frequency to some reasonable
degree but not entirelywithout causing intolerable adverse effects,
the drug was not considered a treatment failure. The Gazi
University Faculty of Medicine Institutional Review Board
approved this study.
Detailed chart review of the patient’s included age, sex,
diagnosis, seizure type, etiology, medication dose and duration
of treatment, the reason for discontinuation of the drug and
adverse effects experienced. The results of any electroencephalog-
raphy or brain imaging were recorded. Etiology was deﬁnedTable 1
Characteristics of the patients treated with ﬁrst-line antiepileptic drug.
Characteristics Seizure-free group
Patients enrolled, n (%) 152 (67.5)
Demographic characteristics
Male, n(%) 81 (53.2)
Female, n (%) 71 (46.7)
Age (years)
Median (range) 8
Mean (SD) 8.2 (0.6)
Age groups
<1, n (%) 14 (63.6)
1–6, n (%) 42 (75)
6–12, n (%) 58 (73.5)
>12, n (%) 38 (55.8)
Clinical details
Seizure type
CPS with sec. generalization 31 (25.6)
Primarily generalized tonic clonic 57 (37.5)
CPS without sec. generalization 14 (9.2)
Absence 20 (13.1)
Myoclonic 13 (8.5)
Infantile spasms 5 (3.2)
Undetermined 4 (2.6)
Etiology
Idiopathic 78 (51.2)
Cryptogenic 46 (30.2)
Syptomatic 31 (20.3)
Treatment details
Antiepileptic drug used
Valproic acid 84 (55.2)
Carbamazepine 33 (21.7)
Oxcarbazepine 22 (14.4)
Others 18 (11.8)
Antiepileptic drug dosage (mg/kg per day)
Valproic acid 22.63.4
Carbamazepine 13.91.4
Oxcarbazepine 27.34.1according to the quidelines of the International League Against
Epilepsy.10 The percentage of patients who failed initial treatment
and the reason for each treatment failure was determined.
Association between the percentage of each failed drugs and age
at onset, seizure types, etiology was determined.
2.2. Statistical analysis
Statistical analysis was performed using Statistical Package for
Social Sciences software, version 11.5 (SPSS Inc., Chicago, IL, 2002).
Data were reported as means with standard error. The major
objective of the study was to study the interaction among drug
treatment failure rates, effectiveness of the ﬁrst antiepileptic drug
prescribed in newly diagnosed pediatric epilepsy. Differences
between number of patients in various subgroups were compared
using chi-square test, and group means were compared using
unpaired two-tailed t-tests. Statistical signiﬁcance was deﬁned as
p < 0.05.
3. Results
3.1. Clinical features
Between January 1, 1999, and December 30, 2005, a total of 502
children were admitted to the Gazi University Pediatric Neurology
Department for seizures. 183were febrile seizures, 85were seen at
another clinic for seizure before and drug was started. Upon being
seen in clinic, 234 patients were newly diagnosed with epilepsy
and started on an antiepileptic drug. The charts of these patients
were reviewed for 5.3 years. Nine patients were lost to follow-up.
Eventually, 225 patients remained for the analyses.Failure group Total p
73 (32.4) 225
41 (56.1) 122 0.965
32 (43.8) 103 0.971
7.5 7.5
7.6 (0.8) 7.5 (0.6) 0.423
0.375
8 (36.3) 22
14 (25) 56
21 (26.5) 79
30 (44.2) 68
0.745
18 (24.6) 49 (21.7)
27 (36.9) 84 (37.3)
7 (9.5) 21 (9.3)
12 (16.4) 32 (14.2)
2 (2.7) 15 (6.6)
13 (17.8) 18 (8)
2 (2.7) 6 (2.6)
0.664
36 (49.3) 114 (50.6)
18 (24.6) 64 (28.4)
16 (21.9) 47 (20.8)
0.856
36 (49.3) 120 (53.3)
12 (16.4) 45 (20)
9 (12.3) 31 (13.7)
11 (15) 29 (12.8)
18.52.9 21.92.6 0.432
13.71.5 13.81.2 0.927
23.53.5 25.64.1 0.456
Table 2
Adverse effects leading to antiepileptic drug failure for the three most commonly
prescribed drugs.
Adverse effect Valproic
acid
Carbamazepine Oxcarbazepine
Increased appetite/weight gain 6 0 0
Rash 0 12 3
Tremor 2 0 0
Headache 1 4 2
Learning problems 1 1 0
Nausea/vomiting 2 3 0
Change in mood 2 2 1
Decreased attention 2 1 0
Tiredness or drowsiness 2 0 1
Somnolence 0 2 1
Dizziness 0 3 2
Hair loss 2 0 0
Thrombocytopenia 1 0 0
Ataxia 1 0 0
Hyponatremia 0 3 1
Total adverse eventsa 22 31 11
Number of patients
drug discontinued**
15 24 8
a Some patients experienced more than one adverse effect.
** Carbamazepine versus valproic acid, p: 0.073; versus oxcarbazepine, p: 0.051.
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included in the study. More than 86% of the patients attended
the clinic for 3.5 years, with follow-up periods ranging from 18 to
72 months. Of the 225 patients analyzed, there were 122 boys
(54.2%), and the mean age of the group was 7.9  0.6 years at
diagnosis. Most of the patients suffered from primarily generalized
tonic-clonic seizures (in 84 patients, 37.3%). The other seizure types
encountered were complex partial seizures with secondary generali-
zation (in 49 patients, %21.7), absence seizures (in 32 patients, 14.2%),
complex partial seizures without secondary generalization (in 21
patients, 9.3%), infantile spasm (in 18 patients, 8%), myoclonic (in 15
patients, 6.6%), undetermined (in 6 patients, 2.6%). In addition, 114
patients (50.6%) were classiﬁed as having idiopathic epilepsy, 64
(28.4%) had symptomatic epilepsy and 47 (20.8%) has cryptogenic
epilepsy.
3.2. Treatment
Valproic acid (n: 120, 53.3%), carbamazepine (n: 45, 20%) and
oxcarbazepine (n: 31, 13.7%) were the most frequently prescribed
antiepileptic drugs. Other ﬁrst-line medications used were
phenobarbital, clobazam, lamotrigine and vigabatrin. Concomitant
antiepileptic drugs used were topiramate, levatiracetam, ethosux-
imide and clobazam.
3.3. Treatment failures
Overall, 67.5% (n: 152) patients were treated successfully with
the ﬁrst antiepileptic drug. Sixteen (7.1%) patients were added on
adjunct antiepileptic drugs without stopping the ﬁrst antiepileptic
drug to achieve a better seizure control during follow-up. In these
patients, the ﬁrst prescribed antiepileptic drug did not totally stop
seizures but decrease seizure frequency, therefore these patients
were not considered treatment failures.
The successfully treated group was compared to the failed
group in terms of age at seizure onset, seizure type, antiepileptic
drug used and drug dose.
A higher proportion of patients with symptomatic and
cryptogenic epilepsy had to discontinue the ﬁrst prescribed
antiepileptic drug because of either intolerable side effects or
lack of efﬁcacy, compared with patients with idiopathic epilepsy
(symptomatic vs. idiopathic:14.1% vs. 4.3%; p: 0.004; cryptogenic
vs. idiopathic:8.5% vs. 4.3%; p: 0.04) (data not shown).
No statistically signiﬁcant differences were seen between two
groups in terms of age at seizure onset, antiepileptic drug used and
drug dose.
3.4. Reasons for treatment failures
Certain age groups (children with seizure onset within the ﬁrst
year), seizure types (infantile spasms, myoclonic, atonic), etiology
(idiopathic, symptomatic, cryptogenic) and antiepileptic drug
selection are considered to be associated with drug treatment
failure in childhood epilepsy.
Seventy-three patients failed with the ﬁrst-line antiepileptic
drug. Of these patients, 28 discontinued medication because of
adverse effects (38.3%), 26 because of lack of efﬁcacy (35.6%) and
19 (26.02%) because of a combination of inefﬁcacy and adverse
effects. Most common adverse event was rashes, which developed
more often with carbamazepine and carbamazepine was discon-
tinued. For valproate, the most frequent side effects causing drug
discontinuation were weight gain and behavioral problems.
Tiredness and dizziness was the most often adverse effect for
oxcarbazepine (Table 2). The rate of discontinuation because of
adverse events was lower among patients on oxcarbazepine but it
was not statistically signiﬁcant.3.5. Age at diagnosis and treatment failures
We compared the treatment failure rates at different age
groups. For the group who failed the ﬁrst-line drug, there was an
inclination toward aged less than 1 year at diagnosis. There were
fewer children agedmore than 10 years at diagnosis. But there was
not a statistically signiﬁcant difference between age groups (chi-
square analysis, p: 0.375) (Table 1).
3.6. Comparison of antiepileptic drugs
Valproic acid, carbamazepine and oxcarbazepine were com-
pared among the children with treatment failure. There was no
statistically signiﬁcant group between the number of failures for
each medication (p: 0.856). Failure rate was 30%, 26.6%, 29% for
valproic acid, carbamazepine and oxcarbazepine, respectively.
Eleven treatment failures occurred in patients treated with other
antiepileptic drugs other than valproic acid, carbamazepine and
oxcarbazepine. All were attributed to lack of efﬁcacy.
Dose of the antiepileptic drug used could also affect the efﬁcacy.
The majority of seizure-free patients used only a moderate daily
dose (valproic acid, 22.45  5.67 mg/kg; carbamazepine, 14.78 
5.03 mg/kg; oxcarbazepine 31.56  7.78 mg/kg). Dosages were also
compared for childrenwith treatment in terms of adverse effects, lack
of efﬁcacy or a combination of both factors (Table 1). There was no
signiﬁcant difference in the doses between seizure-free patients using
valproic acid, carbamazepine and oxcarbazepine and those who had
to change treatment because of intolerable adverse effects in all three
antiepileptic drugs. Although the difference did not reach signiﬁ-
cance, patients who became seizure free took slightly lower doses
than those with the treatment failures because of adverse effects for
all three antiepileptic drugs. In contrast, the children with drug
treatment due to lack of efﬁcacy, the drug doses were slightly higher.
3.7. Effects of speciﬁc seizure types and etiology
There was no signiﬁcant difference (p: 0.664) in the drug
treatment failure rates between the idiopathic, symptomatic and
cryptogenic groups. There was also no statistical signiﬁcance
between the etiology groups in the proportion of patients who
continued the ﬁrst drug.
Likewise, no statistically signiﬁcant difference were found by
analysis for seizure type (p: 0.745) (Table 1).
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Childhood epilepsy in our clinical practice had a generally
favorable outcome, with two-thirds of children achieving remis-
sionwith the ﬁrst antiepileptic drug prescribed. Although there are
many studies dealing with the treatment failure of the ﬁrst
antiepileptic drug in adults, few studies have assessed the drug
treatment failure rates and effectiveness of the ﬁrst antiepileptic
drug in children. Previous studies have reported that the ﬁrst-line
antiepileptic drug will eventually be effective in seizure control in
67–80% of the children.7,9
The present study has two main ﬁndings. The ﬁrst is that in
approximately 30% of the patients ﬁrst-line antiepileptic drug
treatment failed. The second ﬁnding is that adverse events and lack
of efﬁcacy contributed equally to the drug failure.
4.1. Treatment failure rate
Nearly two-thirds of the patients became seizure free and 32%
failure rate was found with the ﬁrst prescribed antiepileptic drug.
Previous studies have largely agreed with this ﬁnding.2,7,9,11
Carpay et al. found 40% of children not responding successfully for
the ﬁrst antiepileptic drug.8 Kwan and Brodie reported a failure
rate less than 50% for patients of all ages, including the 9.8% of their
patient population who were between 9 and 15 years.2 Camﬁeld
et al. obtained more hopeful results for children for whom their
ﬁrst AED failed. They reported a 20% drug treatment failure rate
over the ﬁrst year.7 It should be underlined that Camﬁeld included
only childrenwith generalized tonic clonic, partial and partial with
secondary generalized seizures and did not include treatment
failures due to adverse effects. Therefore, we cannot compare our
results with Camﬁeld directly. Similar ﬁndings, however, have
been reported in trials byMa et al. andDudley et al. recently.9,11Ma
et al. studied a group of 520 children aged <18 years and
investigated the interaction among efﬁcacy, tolerability and
overall effectiveness of the ﬁrst antiepileptic drug in children
with newly diagnosed epilepsy. Overall, 66.2% of the children
became seizure free with the ﬁrst prescribed antiepileptic drug.11
Dudley et al. assessed the percentage of children for whom
antiepileptic drug treatment fails and speciﬁc reasons for
treatment failures. They found that treatment with the ﬁrst
antiepileptic drug failed in 30/95(31.6%) children.9 Moreover,
further clinical studies are needed to validate our observations.
4.2. Antiepileptic drugs
In the present study, valproate, carbamazepine and oxcarba-
zepinewere themost commonly prescribed antiepileptic drugs. All
have similar effectiveness and failure rates. The percentages of
patients who changed the ﬁrst-line antiepileptic drugs both using
valproate, carbamazepine and oxcarbazepine are not signiﬁcantly
different. Although the difference is not statistically signiﬁcant,
patientswho became seizure free took lower doses than thosewith
drug treatment failures because of adverse effects. This represents
the common clinical observation. AED doses are usually progres-
sively increased in patients experiencing ongoing seizures.
Therefore, it is not surprising that they received a higher dose
compared with the seizure-free patients. Those who had adverse
events due to the antiepileptic drugs took a lower dose than the
responding patients, as themajority of withdrawals due to adverse
events occurred at relatively low dosage for all three AEDs. The
reasons for such marked differences are not completely under-
stood. This may be due to the diversity of underlying neuro-
pathologies12,13 and possible genetic variability inﬂuencing drug
response and tolerance.14 These data also support the suggestion of
two distinct populations of patients with newly diagnosedepilepsy [i.e., those responding to monotherapy and those
requiring treatment with more than one AED15].
To the best of our knowledge, the present study is the ﬁrst one
which provided data on treatment failures with a newer
antiepileptic drug, oxcarbazepine. Although statistically not
signiﬁcant, our data may indicate that oxcarbazepine may be
better tolerated than the standard antiepileptic drugs with
equivalent efﬁcacy. Comparative trials should be performed on
the failure rates and reasons for failures of newer antiepileptic
drugs in childhood epilepsy.
4.3. Reasons for drug treatment failure
In the present study, we observed no difference in the
proportion of treatment failure due to adverse effects, lack of
efﬁcacy, or the combination of these. The data we found are
compatible with those reported in previous studies.2,9 Kwan et al.
studied both children and adults. Dudley et al. also found that
adverse effects and lack of efﬁcacy contributed equally to ﬁrst-line
antiepileptic treatment failures in newly diagnosed epilepsy in
children.9 The population we reported on here constituted only
pediatric patients. The proportions that we observed were more
similar to those reported by Dudley et al. The most frequent
adverse effect of carbamazepine treatment necessitating drug
discontinuation was rash. Increased weight gain and behavioral
problems were the most frequent adverse effects among patients
using valproate. No deaths or life threatening adverse events
occurred during the course of this study. Our data indicate that
adverse events were frequent but not severe, and were one of the
main reasons for withdrawal from AED monotherapy.
Variables predictive of the drug treatment failure in childhood
epilepsy were etiology, seizure type and age at onset. Our ﬁndings
were similar to the previous studies.2,9 Dudley et al. found age at
onset below 1 year is associated with treatment failure. Our group
of patients younger than 1 year also showed an inclination toward
treatment failure. Although the results were not statistically
signiﬁcant, only the inﬂuence of age seemed to be correlated with
drug treatment failure.
4.4. Limitations of the study
The main limitation of the study is its retrospective design. In
our center, we increase drug dosage to the maximal recommended
dose or to the point at which the patient showed signs of toxicity
before consider it ineffective. After the drug is accepted as
ineffective, the pediatric neurologist stops the drug because of lack
of efﬁcacy. Antiepileptic drug levels were not routinely measured,
and speciﬁc maximal dose guidelines were not used for this study.
However, it may be possible that some patientsmay have tolerated
a further increase in dose. If antiepileptic drugs were discontinued
prematurely in a small number of subjects, the success rate for the
ﬁrst prescribed antiepileptic drug may be higher than we found.
5. Conclusion
To the best of our knowledge, this is the ﬁrst study that assesses
the efﬁcacy and treatment failure rate of older antiepileptic drugs;
valproate and carbamazepine and a newer antiepileptic drug;
oxcarbazepine in a large group of pediatrics patients with newly
diagnosed epilepsy. The rate of drug discontinuation because of
adverse events was lower among patients on oxcarbazepine but it
was not statistically signiﬁcant. 32.5% of the children with newly
diagnosed epilepsy fail the ﬁrst prescribed antiepileptic drug.
Adverse effects and lack of efﬁcacy contributed equally to the
treatment failures. Although our understanding of the treatment of
childhood epilepsy has improved over the last two decades, much
E. Arhan et al. / Seizure 19 (2010) 553–557 557work lies ahead in this ﬁeld. Future longitudinal prospective
multicenter studies are needed to assess the outcome of
antiepileptic drug treatment. A better understanding of the natural
history of treated epilepsy would allow more accurate assessment
of the factors inﬂuencing drug treatment failure in pediatric
epilepsy and help formulate a strategic approach to management
in patients in whom monotherapy with the ﬁrst-choice AED fails.
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